← Browse by Condition
Medical Condition
recurrent glioblastoma
Total Trials
9
Recruiting Now
9
Trial Phases
Phase 1, EARLY_Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for recurrent glioblastoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — recurrent glioblastoma Clinical Trials
How many clinical trials are currently recruiting for recurrent glioblastoma?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for recurrent glioblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for recurrent glioblastoma?
recurrent glioblastoma research spans Phase 1 (6 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a recurrent glioblastoma clinical trial?
Eligibility criteria for recurrent glioblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 6
Phase 2 4
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07551336 Phase 1
Recruiting
Enrollment
36 pts
Location
China
Sponsor
Beijing Biotech
NCT07648823 EARLY_Phase 1
Recruiting
Enrollment
5 pts
Location
China
Sponsor
Beijing Tiantan Hospital
NCT06613841 EARLY_Phase 1
Recruiting
Enrollment
15 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn...
NCT06273176
Recruiting
Enrollment
225 pts
Location
United States, Belgi...
Sponsor
Erasmus Medical Center
NCT06220552 Phase 2
Recruiting
Enrollment
20 pts
Location
China
Sponsor
Fifth Affiliated Hospital, Sun...
NCT07416188 Phase 1, Phase 2
Recruiting
Enrollment
40 pts
Location
United States
Sponsor
National Institute of Neurolog...
NCT06598787 Phase 2
Recruiting
Enrollment
20 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT07346144 Phase 1, Phase 2
Recruiting
Enrollment
68 pts
Location
United States, Unite...
Sponsor
Trogenix ltd
NCT05577091 Phase 1
Recruiting
Enrollment
10 pts
Location
China
Sponsor
Beijing Tiantan Hospital
Related Conditions
glioblastoma (3) high grade gliomas (2) glioblastoma gbm (2) glioblastoma multiforme of brain (2) malignant glioma (1) recurrent high grade gliomas (1) recurrent glioblastoma who grade iv glioma (1) recurrent glioblastoma idh wildtype (1) glioblastoma idh wildtype (1) astrocytoma malignant (1) brain neoplasms (1) brain neoplasms adult malignant (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology